Aprea Therapeutics, Inc.
Key statistics
from XBRL data in SEC filingsAI briefing
from the latest 10-K, 10-Q and 8-K eventsAprea Therapeutics is a clinical-stage precision medicine oncology company developing synthetic lethality-based small molecule inhibitors, currently led by its WEE1 inhibitor APR-1051 in Phase 1 trials.
What they do
Aprea is a clinical-stage biopharmaceutical company focused on targeted cancer therapies using synthetic lethality. Its lead candidate, APR-1051, is an oral WEE1 inhibitor in a Phase 1 dose-escalation study (ACESOT-1051) for advanced solid tumors. It also has ATRN-119, an oral ATR inhibitor that completed Phase 1/2a dose escalation. The company has no marketed products and no commercial revenues.
Revenue drivers
- APR-1051 (WEE1 inhibitor) — Lead product candidate; no revenue, but early clinical activity in biomarker-defined cancers (uterine serous carcinoma, platinum-resistant ovarian cancer) and planned combination studies.
- ATRN-119 (ATR inhibitor) — Second clinical candidate; monotherapy dose escalation completed, closed to focus on APR-1051; future development in combinations is being considered.
- No commercial products — No approved drugs; no sales revenue; solely funded by equity/debt, including a $30M private placement closed in Q1 2026.
Recent performance
Net loss for 2025 was $12.6M, narrower than 2024's $13.0M. Cash and equivalents were $41.2M as of June 30, 2026. The company reported promising early data from ACESOT-1051: two partial responses (one unconfirmed, one confirmed) in PPP2R1A-mutated endometrial cancer, and stable disease in six patients as of May 6, 2026. Enrollment is expanding from three to ten active sites, aiming for 6-10 patients per month by Q4 2026. Operating cash flow for 2025 was -$12.9M.
Strategy
Aprea is prioritizing APR-1051, accelerating enrollment in ACESOT-1051, and planning to advance it in biomarker-defined populations: uterine serous carcinoma and cyclin E-overexpressing platinum-resistant ovarian cancer. It also plans combination studies with immune checkpoint therapy in HPV-positive head and neck cancer and standard-of-care chemotherapy in colorectal cancer. The company closed its ATRN-119 monotherapy study to focus resources on APR-1051. It is supported by a $30M private placement closed in Q1 2026.
Risks
- Clinical-stage, no revenue — Aprea has never generated commercial revenue and expects to incur losses for the foreseeable future; profitability is uncertain.
- Need for additional capital — With $41.2M in cash, the company will need substantial funding to advance clinical trials and may not secure it on acceptable terms.
- Dependence on early clinical data — APR-1051 is in Phase 1; the confirmed partial response is from a single patient and further data may not replicate.
- Potential Nasdaq delisting — The company received a delisting notice on July 23, 2026, which could impair liquidity and access to public capital markets.
Outlook
Management expects to report next clinical data from ACESOT-1051 at a medical meeting in Q4 2026. Completion of dose escalation and backfill expansion is anticipated in Q2 2027. Enrollment is expected to accelerate, with 6-10 patients per month by Q4 2026.